Steven Leonard Chapman sold $13M of NTRA
CEO AND PRESIDENT at Natera, Inc.. 87,272 shares at an average of $143.40, traded Mar 5, 2025, filed Mar 7, 2025.
Score components
- +25RoleCEO
- +25Trade size$12.5M at market
- +10Share of holdings soldSold 30% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-007466, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | SOpen-market sale Common Stock10b5-1 | -11,978 | $141.91 | $1.7M | 278,648 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock10b5-1 | -30,298 | $142.79 | $4.3M | 248,350 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock10b5-1 | -33,776 | $144.02 | $4.9M | 214,574 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock10b5-1 | -10,320 | $144.75 | $1.5M | 204,254 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock10b5-1 | -900 | $145.42 | $131k | 203,354 | Mar 7, 2025 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 27Weak | Natera, Inc. | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | $116k 792 shares | -1% | |
| 45Moderate | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $979k 6,702 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.